Estrogen receptor beta (ERβ)

Class

Synthetic genistein nanosuspension (radioprotectant, ERβ agonist)

Pathway

Anti-inflammatory / cell-cycle checkpoint activation, protects normal tissue from radiotherapy injury

Estrogen receptor beta (ERβ) is one of two nuclear hormone receptor subtypes—alongside ERα—that mediate cellular responses to estrogenic compounds. Unlike ERα, which is prominent in reproductive tissues and drives proliferative signaling, ERβ is more broadly expressed and is associated with anti-inflammatory and tissue-protective transcriptional programs. Selectively engaging ERβ, rather than activating both receptor subtypes, is a deliberate pharmacological choice: it allows recruitment of protective gene-expression changes without the growth-stimulatory signaling that ERα activation can produce in hormone-sensitive tissue. Genistein, a plant-derived isoflavone with a binding preference for ERβ over ERα, is used here to exploit this distinction. Agonism of ERβ can dampen inflammatory signaling cascades and promote cell-cycle checkpoint activity, giving stressed cells time to repair damage rather than proceeding directly into division. This property underlies interest in ERβ agonists as radioprotectants—agents intended to shield normal tissue from the collateral injury caused by ionizing radiation used therapeutically, such as mucosal or marrow damage. The broader disease relevance of ERβ biology extends beyond radioprotection into inflammatory and hormone-responsive conditions, but its selective, non-ERα-driven activation profile is what makes it attractive wherever proliferative estrogenic stimulation is undesirable.